PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

VOLUME 47, 1994
SUBJECT AND AUTHOR INDEX

PERGAMON

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662

European Editor-in-Chief

SANDRA E. FILE

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK

Editorial Advisory Board

LIISA AHTEE, Helsinki, Finland
LEMBIT ALLIKMETS, Tartu, Estonia
ROBERT L. BALSTER, Richmond, VA
GIOVANNI BIGGIO, Cagliari, Italy
MIKE BRILEY, Castres, France
ALLAN C. COLLINS, Boulder, CO
DONALD V. COSCINA, Toronto, Ontario, Canada
JACQUELINE N. CRAWLEY, Bethesda, MD
ANNETTE DOMENEY, Geneva, Switzerland
ADRIAN J. DUNN, Shreveport, LA
BURR EICHELMAN, Philadelphia, PA
WILLIAM J. FREED, Washington, DC
RICHARD A. GLENNON, Richmond, VA
F. G. GRAEFF, São Paulo, Brazil
M. R. C. GREENWOOD, Davis, CA
ROLAND R. GRIFFITHS, Baltimore, MD
STEPHEN G. HOLTZMAN, Atlanta, GA
AKIRA HORITA, Seattle, WA
CHRIS E. JOHANSON, Baltimore, MD
HAROLD KALANT, Toronto, Ontario, Canada
G. JEAN KANT, Washington, DC
KATHLEEN M. KANTAK, Boston, MA
GEORGE F. KOOB, La Jolla, CA
CONAN KORNETSKY, Boston, MA
J. DAVID LEANDER, Indianapolis, IN
EMINY H. Y. LEE, Taipei, Taiwan
ALLEN S. LEVINE, Minneapolis, MN
WILLIAM J. McBRIDE, Indianapolis, IN
DONALD E. McMILLAN, Little Rock, AR
JACK H. MENDELSON, Belmont, MA
ROBERT D. MYERS, Greenville, NC
JUDITH A. PRATT, Glasgow, UK
ROSARIO SAMANIN, Milan, Italy
HERMAN H. SAMSON, Winston-Salem, NC
PAUL R. SANBERG, Tampa, FL
PHIL J. SKOLNICK, Bethesda, MD
CLARE STANFORD, London, UK
MARIE-HÉLÈNE THIÉBOT, Paris, France
DEREK VAN DER KOOY, Toronto, Ontario, Canada
JEANNE M. WEHNER, Boulder, CO
BRUNO E. WILL, Strasbourg, France
J. C. WINTER, Buffalo, NY
ALICE M. YOUNG, Detroit, MI
IAN S. ZAGON, Hershey, PA

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editorial Office:
Matthew J. Wayner
Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: (210) 691-4510

European Editorial Office:
Sandra E. File
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: 44-(0)71-955-4627

Production Editor:
Jonathan R. Goodnough

Publishing, Subscription, and Advertising Offices:
Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address: ESUK.USA@ELSEVIER.COM; and Elsevier Science Ltd, Headington Hill Hall, Oxford OX3 0BW, UK

Published Monthly

Annual Institutional Subscription Rates (1994): North, Central and South America, US$1440.00, Rest of World £935.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

Pharmacology Biochemistry and Behavior is an official journal of the International Behavioral Neuroscience Society. For information about the society, please contact: Dr. Linda Spear, Department of Psychology, State University of New York at Binghamton, Box 6000, Binghamton, NY 13902-6000, USA. Members of the International Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are available upon request.

Pergamon

Pharmacology Biochemistry and Behavior, Vol. 47, No. 4, pp. III–VIII, 1994
Copyright © 1994 Elsevier Science Ltd
Printed in the USA. All rights reserved
0091-3057/94 $6.00 + .00

SUBJECT INDEX

Abstinence, 107
Activity, 409, 879
Acute toxicity, 273
Adrenergic receptor: α_2, agonist, 171
Age, 567
Aggression, 753
Aging, 41, 325
Agonist, 701
Agonistic behavior, 753
AIT-082, 325
Alcohol, 567, 625
Alcohol consumption, 375
Alcohol deprivation, 625
Alcohol drinking, 385
Alcohol preference, 345
Allopregnanolone, 735
α_1-Adrenergic receptor, 989
α_2-Adrenergic heteroreceptors, 985
α-Helical CRF, 393
ALS, 901
Aluminum, 587
Alzheimer's disease, 41, 833
Amantadine treatment, 451
Ambulatory activity, 101
Amino acids, 59, 493
Amitriptyline, 21
Amphetamine, 203, 345, 369, 413, 579, 803, 907, 963
Analgesia, 177, 197
Anesthesia: hypnosis, 171
Anesthetic(s), 523, 721
Angiotensin antagonist, 385
Angiotensin receptor subtypes, 385
Angiotensin II, 385
Anhedonia, 761
Animal model, 833
Aniracetam, 219
Anorectic activity, 701
Anorexia, 59, 273, 865
Anorexia nervosa, 215
Antagonist, 701
Anticipatory behaviour, 307
Anticonflict effect, 873
Anticonvulsant(s), 443, 839
Antiemetics, 273
Antinociception, 21, 727
Anxiety, 183, 437, 459, 735
Anxiolytic, 1
AOAA, 5
Apomorphine, 77
APV, 493
Area postrema, 363
Arginine^8-vasopressin, 27
Aromatization, 183
Arousal, 283
Associative learning, 289
AT_1 receptor, 385
AT_2 receptor, 385
Ataxia, 709
Aversion, 659
Aversiveness, 255

Baboons, 981
Backward conditioning, 547
Barbiturate, 675
Barrel rotation, 27
Behavior, 13
Behavioral satiety sequence, 307
Behavioral sensitization, 161, 603, 989
Behavioral test, 459
Behavioral toxicology, 363
Benzodiazepine(s), 437, 471, 739, 823
Benzodiazepine receptor, 1, 681
β-Blockers, 873
β-Carbolines, 681, 689
Bicuculline, 351
Bipolar stimulation, 993
Blood pressure, 187
Body composition, 247
Body temperature, 471
Body weight, 255, 273, 427, 659, 865
Brain level of β-carboline, 689
Brainstem, 197
Bromocryptine, 749
Buprenorphine, 379
Buspirone, 153, 947

Ca^{2+}, 355
Caffeine, 89, 153, 919
Calcium channels, 675, 757
Cannabimimetic, 113
Cannabinoid receptors, 33
Cannabinoids, 47
Caramiphen, 709
Carbamazepine, 839
Catalepsy, 509
Catecholamines, 77, 935
CCK-A receptor, 701
CCK-B receptor, 701
Central, 547
C57BL/6, BALB/c, and DBA/2 mice, 375
cFP-AAF-pAB, 715
CGP 40116, 127
CGRP, 121
Channel blocker, 409
Chlordiazepoxide, 153, 845, 947
Chlorimipramine, 803
Choice reaction performance, 219
Cholecystokinin, 701
Choline acetyltransferase activity, 833
Chronic administration, 865
Chronic drug administration, 427
Chronic opioid, 379
Chronic stress, 233, 789
Chrysin, 1
CI-966, 5
Circadian, 65, 409
Circadian rhythms, 471
$^{36}Cl^-$ influx, 355
Classical conditioning, 289, 523
Clonidine, 215, 969
Clozapine, 579
CNS depression, 351
Cocaine, 13, 203, 839, 981, 989, 997
Cocaine addiction, 819
Cocaine hydrochloride, 973
Cocaine methiodide, 973
Cocaine withdrawal, 451
Cognitive, 41
Cognitive changes, 901
Cold stress, 935
Concentric electrode, 993
Concurrent acute exercise, 779
Concurrent schedules, 107
Conditioned taste aversion, 273, 363, 369, 547
Continuous cocaine, 399
Continuous cold-water swims, 727
Convulsion, 689
Copulation, 483
Core body temperature, 65
Core temperature, 27
Cortical neurons, 355
Corticosterone, 943, 947
Corticotropin-releasing factor, 393
Cosinor, 65
Crickets, 493
Critical period, 183
CTOP, 715
Cyclo(leucyl-glycyl) (CLG), 141

D_1 receptor, 101, 369
D_1 and D_2 receptors, 47
D_2 antagonist, 77
D_2 dopamine receptor, 141
D_2 receptor, 101, 331, 369, 553
DA_1 receptor, 749
DA_2 receptor, 749
DAMGO, 827
d-Amphetamine, 89
d,l-Amphetamine, 339
d- and *l*-fenfluramine, 541
DAU 6215, 95
Deficiency, 59
Dehydroepiandrosterone, 437
Dehydroepiandrosterone sulfate, 437
Delta, 715
δ^9-Tetrahydrocannabinol, 47

Denervation supersensitivity, 101
Deoxynivalenol, 363
Dependence, 675
Depression, 985
Descending pathway, 883
Desensitization, 171
Development, 889
Dexfenfluramine, 307
Dexmedetomidine, 171
Dextromethorphan, 709
Diazepam, 241, 739, 927, 947
Dietary choice, 59
Dietary intake, 187
Dihydropyridine, 675
Dihydroxyphenyl-tetrahydrothienopyridine (THP), 483
Discrimination, 113, 317
Discriminative stimulus, 743
Dizocilpine, 443, 839
Dizocilpine (MK-801), 603
DOPAC, 47, 765
Dopamine, 47, 77, 161, 331, 345, 369, 413, 509, 617, 749, 765, 803, 857, 907, 973
Dopamine D_1 receptor, 483
Dopamine receptor antagonists, 575
Dopamine system, 819
Dose–response analysis, 553
Drinking, 207, 339
Drinking behavior, 413, 633
Drug abuse, 857
Drug cue, 107
Drug discriminability, 951
Drug discrimination, 5, 153, 487, 575, 667, 743
Drug effects, 59
Drug self-administration, 13, 981
D3, 647
DuP753, 385
DuP 747, 487
Dynorphin A(1–13), 421

Eating, 207
ECS-induced amnesia, 121
Educed waveform, 65
EEG, 283, 919
8-OH-DPAT, 133, 301, 509, 947
Ejaculation, 883
Electrical stimulation, 993
Electrically induced convulsions, 503
Electroconvulsive shock, 477
Electroconvulsive stimulation (ECS), 647
Elevated plus-maze, 147, 183
Elevated plus-maze test for anxiety, 591
Enantiomers, 113
Endopeptidase 24.15, 715
Energy expenditure, 215
Enkephalins, 771
Epilepsy, 127
Ethanol withdrawal, 443
Ethanol, 147, 227, 345, 351, 355, 437, 547, 743, 795
Eticlopride, 89, 907
Excitatory amino acids, 443
Exercise, 215
Exploration, 427, 879
Exploratory behaviour, 183, 591
Extreme posture, 233

Fawn-Hooded rat, 985
Feeding, 215
Feeding behavior, 59, 255
Fenfluramine, 575
FFA, 851
Field study, 187
5-HT, 307, 541
5-HT receptors, 789
5-HT_{1A} agonist, 133
5-HT_{1A} receptor(s), 301, 873
5-HT_{1C} receptors, 985
5-HT_2 receptor, 301, 553, 667
5-HT_3 receptor, 95, 399
5-HTP, 547
5-Hydroxytryptamine, 591, 803, 865, 883
5-Hydroxytryptophan, 547
Fixed-interval schedule, 997
Flavor, 413
Flesinoxan, 957
Flumazenil, 681
Fluoxetine, 575
Food deprivation, 317, 969
Food intake, 255, 427, 659, 851, 865
Food reinforcement, 379
Forced ambulation, 233
Forebrain, 207
Forward conditioning, 547
4-Aminopyridine, 409
FPL 14294, 701

GABA, 5, 177, 351, 437
$GABA_A$, 913
$GABA_A$ receptor, 177
GABA/Bz receptor, 147
GABA neuroactive steroids, 735
GABA receptor complex, 355
Genetic, 375
Genetics, 721, 889
Gerbils, 113
Global ischemia, 963
Glucoprivic feeding, 317
Glucose metabolism, 833
Glutamate, 907
Glutamic acid, 351
Glycine, 241
Growth hormone, 985
Guide cannula assembly, 993

Habituation, 427
Hallucinogens, 289, 667
Haloperidol, 369, 553, 579, 633, 761, 963
Handling, 765
HAS, 721
Head twitch, 301
Heart rate, 27, 187, 295
[^{3}H]8-OH-DPAT binding, 667
Hindbrain, 207
Hippocampus, 833
Histamine, 503
[^{3}H]Ketanserin binding, 667
Horizontal movement, 827
Hormones, 857
HPLC, 255
Human laboratory, 531
Human satietin, 255
HVA, 765
Hyperactivity, 331
Hyperalgesia, 197
Hyperdipsia, 339
Hypnosis, 567
Hypnotics, 359
Hypoalgesia, 227
Hypophagia, 273
Hypothermia, 567
Hypoxia, 219
Ibogaine, 13
ICV administration, 121
ICV infusion, 255
Imbalance, 59
Imipramine, 427
Immunosuppression, 497
Individual differences, 73
Individual housing, 497
Ingestion, 255
Ingestive behaviors, 413
Inhibitory avoidance, 951
Insects, 493
Insulin, 317
Intact proestrous females, 467
Intake, 133
Interferon, 901
Intermediate stage, 359
Intermittent cocaine, 399
Intermittent cold-water swims, 727
Intracerebroventricular, 21
Intracerebroventricular infusions, 973
Intracerebroventricular injection(s), 587, 743
Intracranial stimulation, 993
Intranasal, 701
Intraperitoneal injection, 587
Intrathecal, 21, 177
Intravenous, 21
In vivo receptor binding, 553
Ipsapirone, 957
[^{125}I]R-DOI binding, 667
Ischemia, 219
Isolation distress, 735
IV self-administration, 819

Japanese quail, 77

Kappa, 715
Kappaergic, 197
Kappa-opioid agonist, 575
κ-Opioid analgesic, 487

Lactate, 779
Lactation, 857
L-Amphetamine, 41
LAS, 721
Lateral hypothalamus, 247
L-Deprenyl, 41
Lead, 227
Lean, 625
Learning, 477, 523, 647, 681, 833
LEK-8804, 301
Lever press, 997
L-Glutamate, 351
Licking, 997
Limbic forebrain, 33
Limited access, 375
Lisuride, 819
Lithium, 73
Lithium chloride, 547
Locomotion, 427, 591, 879
Locomotor activity, 603, 709, 827, 839, 907, 969
Locus coeruleus, 171
Long-term memory, 493
Losartan, 385
Loss of righting reflex, 351
Lysergic acid diethylamide (LSD), 667

Macronutrient selection, 273
Male and female rats, 997
Male sexual behavior, 77, 591

MAO-A, 41
MAO-B, 41
Marijuana, 47, 113
Masking, 153
Matching-to-sample, 935
Maternal, 927
Maternal behavior, 857
Maternal separation, 735
*m*CPP, 541
MDMA, 289, 369
Meadow voles, 265
Medial preoptic area, 483
Medial vestibular nucleus, 739
Memory, 283, 477
Memory consolidation, 493
Memory deficit, 325
Mesolimbic, 331
Metergoline, 307
Methadone, 379
Methamphetamine, 161, 219, 879
Methamphetamine sensitization, 101
Methcathinone, 981
Methodology, 531
Metoclopramide, 273
Mice, 325, 437, 753, 839
Microdialysis, 161, 765, 973
Microinjection, 743
Microwave exposure, 845
Midazolam, 5
Midbrain transection, 207
MK212, 541
MK-801, 127, 443, 907
Molecular modeling, 667
Monoamine oxidase, 41
Morphine, 339, 421, 559, 633, 765, 969
Morris water maze, 95, 265, 477
Motor activity, 47, 437
Motor behaviour, 127
Motoric deficit, 761
Mouse, 127, 219
Mouse staircase test, 845
Mu, 715
μ-Opioid peptide agonist, 827
μ_2-Opioid receptor, 943
Muscimol, 177
Muscle and brain, 779

Naloxone, 265, 493, 541
Naltrexone, 559
Naltrindole, 715
NAN-190, 301, 957
Narcolepsy, 65
Nasal spray, 295
Natural compound, 1
Nausea, 273
NCAM, 647
Neonates, 857
Neuroleptics, 141, 761
Neuromodulation, 493
Neuropeptide Y, 207
Neurotoxicity, 901
Nicotine, 197, 295, 331, 889, 919
Nicotinic receptors, 889
Nictitating membrane, 289
Nictitating membrane response, 523
Nigrostriatal, 331
Nigrostriatal dopaminergic neurons, 47
Nipple shifting, 133
N-Isopropyl lysergamides, 667
Nitric oxide, 727
Nitrous oxide, 523
NMDA, 493
NMDA antagonist, 127
NMDA receptor antagonists, 823
NMDA receptors, 907
N^{ω}-*Nitro*-L-arginine, 727
NO, 493
Nociception, 177, 197
Nonassociative learning, 289
Nonopioid, 727
Nootropic drug, 283
Nor-binaltorphimine, 715
(−)-Norpseudoephedrine, 339
NS-3, 477
Nucleus accumbens, 345, 765

Obese, 625
Octapeptide, 701
Office vs. nonoffice work, 187
Ondansetron, 59, 633
Ontogeny, 133, 161, 927
Open-field, 113, 459
Operant, 113
Operant behavior, 559
Operant responding, 515
Opiate agent, 789
Opiates, 265
Opioid(s), 197, 493, 715, 727, 927
Opioid antagonists, 559
Opioid peptides, 421
Organ growth, 247
Oxiracetam, 283
Oxytocin, 273

Pain, 21, 177
Palatability, 73, 307, 413
Paradoxical sleep, 359
Parkinson's disease, 41
Passive avoidance behaviour, 121
Passive avoidance memory, 587
p-Chloramphetamine, 803
PCP, 579
PCPA, 957
PD123319, 385
Pentobarbital, 5, 879
Pentylenetetrazol, 241
Pentylenetetrazole-induced convulsions, 503
Peripheral, 547
Pharmacogenetics, 443
Pharmacology, 59
Phencyclidine (PCP), 603, 709
Phenobarbital, 951
Phenytoin, 951
Phosphoinositide hydrolysis, 989
Physical activity, 187
Physiology, 59
Physostigmine, 325, 779
Pica, 273
Pigeons, 113
Pimozide, 515
Pindolol, 957
Place conditioning, 973
Place preference, 771, 907
Plasma, 779
Plasma substrates, 247
Potassium, 409
Prazosin, 851
Preference, 625, 795
Pregnancy, 857
Pregnanolones, 177
Preoptic area, 77
Prewatering, 761
Procaine hydrochloride, 973
Proceptivity, 467
Procognitive drugs, 757
Progesterone, 177
Progestins, 177
Progressive ratio, 379
Prolactin, 857
Protein malnutrition, 789
Psychedelics, 289
Psychomotor stimulants, 981
Purine, 325
Pygmy goats, 851
Pyruvate, 779

Quinine, 73, 413
Quinpirole, 89

Rabbit, 289, 523
Raclopride, 369, 509, 753
Radial arm maze, 963
Radial maze, 283
Rat(s), 21, 41, 59, 147, 219, 233, 241, 307, 317, 359, 363, 379, 393, 399, 427, 451, 459, 509, 515, 541, 721, 735, 757, 761, 795, 865, 907, 957, 969, 973, 989
Rat behavior, 587
Rat fetus, 715
Rat pups, 947
Rearing, 827
Receptivity, 467
Receptor complex, 913
Receptor-selective opioids, 421
Receptors, 27
Recovery of function, 963
Reinforcement, 107, 413
Reinforcement value, 515
Removable electrode, 993
Renin–angiotensin system, 385
Resistance to change, 515
Response duration, 761
Retrieval, 587
Reverse tolerance, 603
Reward, 515, 973
Rhythm, 409
Righting reflex, 739
Risperidone, 553
RN 72026-83-6, 255, 659
Ro 15-4513, 147
Route of administration, 487
Rubidium, 409

Saccharin, 307, 541, 547
Saliva cotinine, 187
Salt hunger, 617
Salt intake, 609
Sarthran, 385
Satiety, 659
SCH23390, 89, 101, 369, 749
Schedule-controlled behavior, 421
Schedule-induced alcohol consumption, 997
Schedule-induced polydipsia, 393
Schizophrenia, 141
Scopolamine, 95
Seizures, 241, 443
Selected mouse lines, 443
Selective breeding, 721
Self-administration, 203, 795
Self-stimulation, 803
Sensitization, 13
Sensitization, 203, 289, 345, 451, 559, 823
Sequential behaviour, 647
Serotonin, 59, 183, 467, 509, 547, 617

Serotonin receptor antagonists, 575
Serotonin$_{1A}$ receptors, 467
Serotonin$_2$ receptors, 467
Serotonin$_3$ receptor, 59
7-Chlorokynurenic acid, 241
Sex differences, 265, 997
Sexual behavior, 467, 771
Sexual behaviour and orientation, 183
Sexual differentiation, 183
Sexual reflexes, 883
Shuttle behavior, 219
Shuttle box, 757
Shuttlebox avoidance, 147
6-OHDA, 345
SK&F38393, 89
Sleep, 359
Sleep time, 351
Smoked cocaine-base, 531
Smokers, 107
Smoking, 295
Social behavior, 579
Sodium appetite, 617
S100, 647
Spatial acquisition, 265
Spatial discrimination test, 681
Spatial learning, 95
Spinal cord, 177
Spiradoline, 487, 575
Sprague–Dawley, 625
Squirrel monkey(s), 421, 471
Starvation, 215
State-dependency, 951
Stereoselectivity, 113
Stereotypic behavior, 47
Stereotypy, 603, 709, 827
Steroids, 913
Stimulus, 113
Stimulus termination, 421
Streptozotocin, 833
Stress, 265, 393, 497, 617, 727, 913
Stress-induced antinociception, 927
Stress ulcers, 749
Striatum, 33, 765
Structure–activity relationship (SAR), 113
Subjective effects, 295
Suckling, 133
Suckling maintenance, 133
Sucrose, 73
Sucrose intake, 515
Sulpiride, 89, 749
Supersensitivity, 141
Synaptic remodelling, 647
Synaptophysin, 647

Tachykinin, 609
Tachykinin receptors, 609
Tacrine, 325
Tail flick, 227, 301
Tardive dyskinesia (TD), 141
Taste, 73, 413
Taste aversion, 73
Taste aversion learning, 795
Taste preference, 541
Taste reactivity, 73, 413
Temporal isolation, 65
Testosterone, 591
Tetrahydrocannabinol, 113
TFMPP, 541
THC, 33
THC cue, 113
Theta rhythm, 359
3α-Hydroxy-5α-pregnan-20-one, 735
Tiagabine, 5
Time course study, 553
T-maze, 951
Tobacco smoking, 107
Tolerance, 33, 171, 379, 451, 523, 567, 675, 739, 823
Transmitter mediation, 121
Tremor, 689
TRH, 477
Triazolam, 471
Trichothecene mycotoxin, 363
Trimethobenzamine, 273
TRIMU-5, 943
Two-bottle test for aversion, 659
2-Deoxy-D-glucose, 317
2-Thiazolylethylamine, 503
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD), 273
Tyrosine, 935
Tyrosine hydroxylase, 47

Ultralight cigarette, 187
Ultrasonic vocalizations, 735
Ultrasound, 947
Unconditioned reflex, 289
Urethrogenital reflexes, 883

Valproic acid, 5
Vasopressin, 587
Vasopressin receptor antagonists, 27
Ventral mesencephalon, 33
Ventral striatum, 345
Vigabatrin, 5
Vomitoxin, 363

Water intake, 255, 427, 659
Water maze, 41
Weanling rats, 247
Withdrawal, 399, 633, 675, 919
Within-session effects, 761
Working memory, 325, 935
WSP, 443
WSR, 443

Xylamidine, 547

YM-09151-2, 101

Zolpidem, 359
Zucker, 625

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 47 1994

AUTHOR INDEX

Absil, P., 77
Ågmo, A., 771
Aguilar, M. A., 753
Ahlenius, S., 509
Airaksinen, M. M., 681
Akiyama, K., 161
Albonetti, E., 591
Allen, M., 827
Anderson, K., 997
Andersson, G., 947
Andrade, M., 467
Anisman, H., 497
Aravich, P. F., 215
Atrens, D. M., 369
Aulakh, C. S., 985

Baars, A. M., 27
Babbini, M., 969
Babu, S. R., 779
Bacchi, A., 969
Baker, R. C., 721
Balster, R. L., 5
Balthazart, J., 77
Barber, D. J., 541
Bartoletti, M., 969
Bättig, K., 187
Bauer, A., 857
Bellinger, L. L., 255, 659
Bernardis, L. L., 247
Bernstein, H.-G., 587
Beverly, M., 857
Beyer, C., 177
Billington, C. J., 317
Binkerd, K., 547
Blanco, M. E., 493
Block, A. K., 795
Blokland, A., 833
Blosser, J. C., 701
Bodnar, R. J., 727
Bole-Vunduk, B., 301
Booij, L. H. D. J., 21
Borg, P. J., 633
Borsini, F., 95
Boulos, Z., 471
Bowen, S. E., 761
Brambilla, A., 95
Bratton, G. R., 227
Brauer, L. H., 531
Breen, L., 233
Broder, L., 617
Brown, J., 675
Brunelli, S. A., 735
Buckenmeyer, P. J., 779
Bunker, E. B., 919
Burkey, R. T., 227
Butterworth, A. R., 675

Caba, M., 177
Caldarola-Pastuszka, M., 467
Cancela, L. M., 789
Cannon, D. S., 795
Carretta, J. C., 515
Cavoy, A., 283
Chakravarti, A. K., 749
Chan, A. W. K., 567
Chojnacka-Wójcik, E., 873
Chow, S., 375
Christie, M. J., 369
Ciccocioppo, R., 609
Cleary, J., 379
Cleary, J. P., 317
Cohen, C., 919
Cole, B. J., 393
Collins, A. C., 889
Cooper, S. J., 541
Correa-Sales, C., 171
Cortizo, L., 509
Crabbe, J., 443
Crosby, R., 531

Dajas, F., 1
Darlington, C. L., 739
Das, S., 77
Davis, J. M., 989
de Caro, G., 609
de Costa, B. R., 715
Deitrich, R. A., 721
Delacour, J., 283
Depoortere, H., 359
Deutsch, S. I., 913
de Wied, D., 27
Diamant, M., 27
Dirksen, R., 21
Dokko, J. H., 617
Domino, E. F., 603
Dorow, J., 443
Draski, L. J., 721
Drucker, G. E., 141

Eaton, R. C., 483
Edwards, S., 865
Eguchi, N., 689
Eisenberg, R. M., 943
Ellinwood, E. H., Jr., 399, 451
Engel, J. A., 345
Engh, K., 141
Epstein, L. H., 107
Escorihuela, R. M., 147

Fahlke, C., 345
Farabollini, F., 591
Färkkilä, M., 901
Ferko, A. P., 351
Fernandes, C., 823
Fernández-Ruiz, J. J., 33, 47
Fernández-Teruel, A., 147
Fields, J. Z., 141
File, S. E., 823
Filip, M., 873
Fonte, C., 107, 295
Fraioli, S., 339
Frambes, N. A., 133
Frankmann, S. P., 617
Fujiwara, Y., 161

Gaiardi, M., 969
Galea, L. A. M., 265
Garrett, B. E., 89
Gauvin, D. V., 153
Gelowitz, D. L., 41
Ghoneim, M. M., 523
Gietzen, D. W., 59
Glasky, A. J., 325
Glass, J., 531
Glick, S. D., 765
Gomez, M., 771
Gonzalez, M. I., 183, 591
González-Mariscal, G., 177
Goodwin, G. A., 133
Gordon, J. H., 141
Gormezano, I., 523
Gorriti, M. A., 33
Gorzalka, B. B., 993
Gottesmann, C., 359
Graham, A. L., 857
Grech, D. M., 5
Griffiths, R. R., 981
Grobe, J., 107
Grobe, J. E., 295
Groen, B., 879
Grupp, L. A., 385
Gubellini, C., 969
Gunion, M. W., 207
Guo, T.-Z., 171

Hamann, S. R., 197
Hamilton, J., 659
Hansen, S., 345
Hanson, K., 531
Hård, E., 345
Harding, S., 385
Harford, R., 935
Harvey, J. A., 289
Hasenfratz, M., 187
Hashim, A., 13
Hashimoto, Y., 689
Hatsukami, D. K., 531
Hauger, R., 233
Hayashi, T., 689
Hayashi, Y., 171
Hemby, S. E., 973
Henningfield, J. E., 919
Hernández, M. L., 47
Heydari, N., 325
Higgins, G. A., 307
Hill, J. L., 985
Himori, K., 219
Hirst, M., 363
Hitri, A., 913
Hodge, C. W., 743
Hofer, M. A., 735
Hoffman, D. C., 907
Hokkanen, L., 901
Holloway, F. A., 153
Holm, S., 427
Holtzman, S. G., 89, 421, 487, 559, 575
Houpt, T. A., 471
Huang, X., 667
Hubert, G. W., 973
Hull, E. M., 483
Hulse Neufeld, J., 233
Hurt, W. D., 845

Iinuma, K., 503
Ijaz, S., 963
Irazabal, Y., 771

Jackson, D. E., 761
Jackson, D. M., 369
Jacober, A., 187
Jaffe, K., 493
Järbe, T. U. C., 113
Javaid, J. I., 989
Jiang, J. C., 59
Johnson, D. W., 765
Jolles, J., 833
Jones, D. N. C., 421
Jones, G. H., 973
Jørgensen, O. S., 647
Joyner, C., 451
Joyner, C. M., 399
Justice, J. B., Jr., 973

Kaczmarek, L., 757
Kaminski, B. J., 981
Kanzaki, A., 161
Karanth, K. S., 951
Katz, J. L., 709
Kavaliers, M., 265
Kawanishi, K., 689
Keller, E. A., 789
Khan, A., 477
Kido, H., 553
King, G. R., 399, 451
Kinsley, C. H., 857
Kitchen, I., 927
Klauenberg, B. J., 845
Klemfuss, H., 409
Klint, T., 947
Knowlton, R. G., 779
Ko, J., 375

Koob, G. F., 393, 819
Kovács, A., 121
Kovács, G. L., 27
Kowalski, K., 935
Kripke, D. F., 409
Krisch, I., 301
Kruse, C. B., 515
Kumar, K. B., 951
Kuribara, H., 101

Lai, C.-T., 41
Lai, H., 477
Lajtha, A., 13
Lê, A. D., 375
Leeb, K., 413
Leeka, J. K., 795
Leret, M. L., 183
Levine, A. S., 317
Lin, H. Q., 369
Little, H. J., 675
Lumley, L. A., 483

Macenski, M. J., 379
Markowski, V. P., 483
Marona-Lewicka, D., 667
Marson, L., 883
Martin, W. R., 197
Massi, M., 609
Maswood, S., 467
Maze, M., 171
McGregor, I. S., 369
McKenna, K. E., 883
McLaurin, B. I., 827
Mechoulam, R., 113
Medina, J. H., 1
Mehta, A. K., 355
Melchior, C. L., 325, 437
Mendel, V. E., 255
Merritt, J. H., 845
Meyer, Melissa E., 827
Meyer, Merle E., 827
Miñarro, J., 753
Mirolo, M. H., 477
Mishima, K., 219
Mogensen, J., 427, 647
Molina, V. A., 789
Moody, C. A., 133
Moon, Y., 523
Mori, H., 553
Morley, J. E., 207
Moses, J., 483
Muhammad, B. Y., 927
Murphy, D. L., 985

Nacif-Coelho, C., 171
Nagy, J., 659
Nation, J. R., 227
Navarro, M., 47
Neill, D. B., 973
Nelson, R., 531
Nencini, P., 339
Nichols, D. E., 667
Niemi, M.-L., 901
Nieminen, S. A., 681
Nikolaev, E., 757
Núñez, J. F., 147

Olds, M. E., 803
Olivier, B., 957
Onodera, K., 503
Orlowski, M., 715
Orsingher, O. A., 789
Ossenkopp, K.-P., 265, 363

Paladini, A., 1
Palomo, T., 33
Pandey, S. C., 989
Papanikolaou, A., 579
Park, C. H., 913
Parker, L., 413
Parker, L. A., 73
Pedersen, S. L., 647
Pedersen, T. K., 427
Peirce, J. M., 153
Pentel, P. R., 531
Pérez-Iranzo, N., 753
Perkins, K. A., 107, 295
Peterson, S. L., 241
Petrov, E. S., 715
Pfaff, R. C., 667
Philippens, I. H. C. H. M., 879
Pickworth, W. B., 919
Pirzadeh, B., 325
Pitsikas, N., 95
Poeggel, G., 587
Pohjanvirta, R., 273
Polidori, C., 609
Pollak, C. P., 65
Pompei, P., 609
Poulos, C. X., 307
Poutiainen, E., 901
Prunell, M., 147
Przegaliński, E., 873
Pulvirenti, L., 819
Puri, S., 749

Quan, B., 375
Quock, R. M., 845

Rabbani, M., 675
Railoma, O., 681
Ramalingam, S., 951
Ramos, J. A., 33, 47
Rapley, W. A., 363
Ray, A., 749
Reid, K., 171
Reiser, M., 587
Renton, C., 497
Reynolds, W. A., 295
Rice, K. C., 715
Richardson, J. S., 41
Richardson, S. A., 331
Rieg, T. S., 215
Ritzmann, R. F., 141, 325, 437
Robinson, S. R., 715
Rodríguez de Fonseca, F., 33, 47
Romano, A. G., 289
Rosamond, J. R., 701
Rossi, R., 851

Sakamoto, H., 553
Saksida, L., 265
Salamone, J. D., 579
Schaal, D. W., 317, 379
Scharrer, E., 851
Schenk, S., 203
Schmidt, W. K., 487
Schrot, J., 935
Schuh, K. J., 317
Schulze, H. G., 993
Schwarzberg, H., 587
Scott, S. J., 739
Seidleck, B. K., 839
Sellers, E. M., 307
Sen, P. A., 749
Sershen, H., 13
Sexton, J. E., 295
Shanks, N., 497
Sharpe, L. G., 709
Shiba, K., 553
Shuaib, A., 963
Shurtleff, D., 935
Simmons, R. D., 701
Simón, V. M., 753
Slangen, J. L., 957
Smith, G. P., 617
Smith, P. F., 739
Smotherman, W. P., 715
Sokolowski, J. D., 579
Soliman, K. F. A., 625
Somani, S. M., 779
Spear, L. P., 133
Spinella, M., 727
Sprague, J. E., 547
Starr, B. S., 127
Starr, M. S., 127
Steinfels, G. F., 487, 575
Steinman, J. L., 207
Steinpreis, R. E., 579
Stevens, R., 865
Stiller, R. L., 295
Stino, F. K. R., 625
Stout, J. C., 459
Sumiyoshi, T., 553
Suzuki, K., 553
Székely, J. I., 709

Tatarczyńska, E., 873
Taylor, D. A., 633
Telegdy, G., 121
Thomas, J. R., 935
Thompson, T., 317, 379
Thurkauf, A., 839
Ticku, M. K., 355
Titievsky, A. V., 681
Tizabi, Y., 331
Tobeña, A., 147
Tomkins, D. M., 307
Trefouret, S., 359
Tsuchida, K., 161
Tuomisto, J., 273
Turco, D., 857

Uchihashi, Y., 101
Ujike, H., 161
Ukai, Y., 477
Unkila, M., 273
Uphouse, L., 467
Urasaki, K., 553

Valadez, A., 203
Van De Kamp, J. L., 889
van Diejen, D., 21
Van Golf-Racht, B., 283
van Haaren, F., 997
Van Liew, J. B., 247
van Luijtelaar, E. L. J. M., 21
Varlinskaya, E. I., 715
Vigorito, M., 515
Viola, H., 1

Wadenberg, M.-L., 509
Wagner, D. R., 65
Watanabe, T., 503
Weiss, J. M., 459
Wellman, J., 857
White-Gbadebo, D., 559
Wichlinski, L. J., 141
Wilson, C. A., 591
Wishart, T. B., 41, 963
Witkin, J. M., 839
Wolfman, C., 1
Wolthuis, O. L., 879

Xu, X., 603

Yamaguchi, N., 553
Ybema, C. E., 957
Yokogawa, K., 553
Yokoyama, H., 503
York, J. L., 567
Young, E. R., 443
Yu, P. H., 41

Zabik, J. E., 547
Zahalka, J., 113
Zalcman, S., 497
Zimmerberg, B., 735